Farletuzumab-MMAE (anti-FOLR1) is an antibody-drug conjugate (ADC) composed of humanized anti-human folate receptor-alpha (FRα) and the cytotoxic agent monomethyl auristatin (MMAE) via a MC-Vc linker. It has a potent antitumor activity. Purity >90% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂
No
储存条件
-80℃储存,避免反复冻融
运输条件
特低温运输
稳定性与储存
在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
图片
Farletuzumab-MMAE (anti-FOLR1) (Ab183319) - Flow Cytometry Flow Cytometry analysis of Hela cells labelling FOLR1 (red) with Farletuzumab-MMAE (anti-FOLR1) (Ab183319). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Farletuzumab-MMAE (anti-FOLR1) (Ab183319) - Flow Cytometry Flow Cytometry analysis of MCF-7 cells labelling FOLR1 (red) with Farletuzumab-MMAE (anti-FOLR1) (Ab183319). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Farletuzumab-MMAE (anti-FOLR1) (Ab183319) - SEC The purity of Farletuzumab-MMAE (anti-FOLR1) (Ab183319) is more than 95% verified by HPLC.
Farletuzumab-MMAE (anti-FOLR1) (Ab183319) - ELISA Immobilized Recombinant Human FOLR1 protein (rp167844) at 1.0 μg/mL can bind Farletuzumab-MMAE (anti-FOLR1) (Ab183319) with the EC₅₀ of 36.63 ng/mL.